How Smith & Nephew plc stacks up

SNN · against 454 other Healthcare companies listed in US-listed

Growth

59/ 100

Below the middle of the pack.

Ranked #250 of 455 · scores higher than 44% of peers

Bars: peers in each 10-point band of the growth score

45 peers with a growth score of 50–59, including SNN · Click a bar to see the companies

Why growth scores 59?

Weighted metrics compared with all Healthcare companies.

Its metrics sit close to the Healthcare norm.

3-year revenue growth is close to the peer norm. 3-year revenue growth: 5.7% vs peer median 5.8%
Revenue growth is close to the peer norm. Revenue growth: 6.1% vs peer median 6.1%
faster growth in earnings per share: stronger than 77% of peers. Earnings per share growth: 51.7% vs peer median 9.8%

Metric by metric

Position: dot = SNN, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.

Metric	SNN	Peer median	Better than	Weight
Revenue growthHigher is better · 475 reported	6.1%	11.0%	37%	33%
Earnings per share growthHigher is better · 171 reported	51.7%	21.2%	66%	33%
3-year revenue growthHigher is better · 433 reported	5.7%	11.0%	35%	33%

Ranking by growth score

Top 5 and the companies ranked around SNN

Rank	Company	Market cap	Growth	Overall
1	Phathom Pharmaceuticals, Inc.PHAT · US-listed	464M USD	100	53
2	AnaptysBio, Inc.ANAB · US-listed	1.4B USD	99	73
2	CorMedix Inc.CRMD · US-listed	433M USD	99	81
2	ImmunityBio, Inc.IBRX · US-listed	8.8B USD	99	31
2	Insight Molecular Diagnostics Inc.IMDX · US-listed	90M USD	99	27
⋯
250	Cerus CorporationCERS · US-listed	472M USD	59	33
250	Enovis CorporationENOV · US-listed	1.2B USD	59

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score